The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
MHC Class II epitope predictive algorithms
Open accessAbstract
Summary: Major histocompatibility complex class II (MHC‐II) molecules sample peptides from the extracellular space, allowing the immune system to detect the presence of foreign microbes from this compartment. To be able to predict the immune response to given pathogens, a number of methods have been developed to predict peptide–MHC binding. However, few methods other than the pioneering TEPITOPE/ProPred method have been developed for MHC‐II. Despite recent progress in method development, the predictive performance for MHC‐II remains significantly lower than what can be obtained for MHC‐I. One reason for this is that the MHC‐II molecule is open at both ends allowing binding of peptides extending out of the groove. The binding core of MHC‐II‐bound peptides is therefore not known a priori and the binding motif is hence not readily discernible. Recent progress has been obtained by including the flanking residues in the predictions. All attempts to make ab initio predictions based on protein structure have failed to reach predictive performances similar to those that can be obtained by data‐driven methods. Thousands of different MHC‐II alleles exist in humans. Recently developed pan‐specific methods have been able to make reasonably accurate predictions for alleles that were not included in the training data. These methods can be used to define supertypes (clusters) of MHC‐II alleles where alleles within each supertype have similar binding specificities. Furthermore, the pan‐specific methods have been used to make a graphical atlas such as the MHCMotifviewer, which allows for visual comparison of specificities of different alleles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
Sette, A., & Sidney, J. (1999) · Immunogenetics · doi:10.1007/s002510050594 · Cited by 635
Hillen, N., Mester, G., Lemmel, C., Weinzierl, A. O., Müller, M., Wernet, D., Hennenlotter, J., Stenzl, A., Rammensee, H., & Stevanović, S. (2008) · European Journal of Immunology · doi:10.1002/eji.200838632 · Cited by 43
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Improved methods for predicting peptide binding affinity to MHC class II molecules
Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan, Z., Sette, A., Peters, B., & Nielsen, M. (2018) · Immunology · doi:10.1111/imm.12889 · Cited by 794
Self-citationNeoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Metadata
- Authors
- Nielsen, M., Lund, O., Buus, S., & Lundegaard, C.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2010-06-09
- Volume
- 130
- Issue
- 3
- Pages
- 319-328
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2160303218
- Cited by
- 236
- References
- 2
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MHC Class II epitope predictive algorithms. https://app.cochat.ai/papers/10.1111/j.1365-2567.2010.03268.x
- The paper
- Nielsen, M., Lund, O., Buus, S., & Lundegaard, C. (2010). MHC Class II epitope predictive algorithms. Immunology. https://doi.org/10.1111/j.1365-2567.2010.03268.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.